See more : City Office REIT, Inc. (CIO) Income Statement Analysis – Financial Results
Complete financial analysis of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biohaven Pharmaceutical Holding Company Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- GMR Airports Infrastructure Limited (GMRINFRA.NS) Income Statement Analysis – Financial Results
- BioInvent International AB (publ) (BINV.ST) Income Statement Analysis – Financial Results
- ReoStar Energy Corp. (REOS) Income Statement Analysis – Financial Results
- QAD Inc. (QADA) Income Statement Analysis – Financial Results
- Ur-Energy Inc. (URE.TO) Income Statement Analysis – Financial Results
Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
About Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 462.51M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.37M | 1.39M | 91.66M | 72.00K | 0.00 | 0.00 |
| Gross Profit | -3.37M | -1.39M | 370.85M | -72.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 80.18% | 0.00% | 0.00% | 0.00% |
| Research & Development | 373.28M | 437.07M | 181.49M | 98.46M | 344.67M | 0.00 |
| General & Administrative | 56.90M | 130.86M | 37.41M | 16.05M | 134.45M | 0.00 |
| Selling & Marketing | 5.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 62.77M | 130.86M | 37.41M | 16.05M | 134.45M | 0.00 |
| Other Expenses | 0.00 | -1.91M | 1.21M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M | 0.00 |
| Cost & Expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M | 0.00 |
| Interest Income | 17.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | -12.71M | 0.00 |
| Depreciation & Amortization | 6.91M | 1.39M | 1.39M | 72.00K | 171.86K | 52.52K |
| EBITDA | -429.14M | -462.80M | -217.51M | -114.43M | -479.12M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -47.03% | 0.00% | 0.00% | 0.00% |
| Operating Income | -436.05M | -567.93M | -218.90M | -114.51M | -479.12M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -47.33% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 26.50M | -1.91M | 6.47M | -4.16M | -49.26M | 0.00 |
| Income Before Tax | -409.55M | -569.84M | -212.43M | -118.67M | -528.39M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -45.93% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.38M | 438.00K | 1.37M | -134.30K | 419.00K | 0.00 |
| Net Income | -408.17M | -570.28M | -213.80M | -118.67M | -528.81M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -46.23% | 0.00% | 0.00% | 0.00% |
| EPS | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0.00 |
| EPS Diluted | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0.00 |
| Weighted Avg Shares Out | 71.20M | 44.74M | 35.82M | 35.82M | 48.49M | 0.00 |
| Weighted Avg Shares Out (Dil) | 71.20M | 44.74M | 35.82M | 35.82M | 48.49M | 0.00 |
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
Why Biohaven Stock Is Crashing Today
2 Growth Stocks With Major Incoming Catalysts
Why Biohaven Stock Caught Fire This Week
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
Source: https://incomestatements.info
Category: Stock Reports